pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX
TG THERAPEUTICS
TG THERAPEUTICS, INC.
TG THERAPEUTICS is a pharma organization headquartered in Morrisville, USA. It trades on NYSE under ticker TGTX. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia, Relapsing Multiple Sclerosis, Hodgkin
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US HQ
2011 Founded
521 Employees
Public company Type
TGTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
- Founded
- 2011
- Employees
- 521
- Programs
- 39
- Drugs
- 23
- Patents
- 7
Ublituximab
Phase 2 · small molecule · Non-Hodgkins Lymphoma
Ublituximab for Non-Hodgkins Lymphoma is a Phase 2 program (small_molecule) at TG THERAPEUTICS, INC. with 2 ClinicalTrials.gov record(s).
Internal code TGTX 1101-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- TG THERAPEUTICS, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Non-Hodgkins Lymphoma
- Status
- completed
- Trials
- 2